{"id":"NCT04502693","sponsor":"GlaxoSmithKline","briefTitle":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","officialTitle":"A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-14","primaryCompletion":"2022-09-13","completion":"2022-09-13","firstPosted":"2020-08-06","resultsPosted":"2024-03-05","lastUpdate":"2024-03-05"},"enrollment":3657,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"rMenB+OMV NZ vaccine","otherNames":["Bexsero"]},{"type":"BIOLOGICAL","name":"Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)","otherNames":["Menveo"]},{"type":"COMBINATION_PRODUCT","name":"Placebo","otherNames":["NaCl, saline solution"]},{"type":"COMBINATION_PRODUCT","name":"MenABCWY-1","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"MenABCWY-2","otherNames":[]},{"type":"COMBINATION_PRODUCT","name":"MenABCWY-3","otherNames":[]}],"arms":[{"label":"MenB_0_2_6 Group","type":"EXPERIMENTAL"},{"label":"MenB_0_6 Group","type":"EXPERIMENTAL"},{"label":"ABCWY-1 Group","type":"EXPERIMENTAL"},{"label":"ABCWY-2 Group","type":"EXPERIMENTAL"},{"label":"ABCWY-3 Group","type":"EXPERIMENTAL"},{"label":"ACWY Group","type":"ACTIVE_COMPARATOR"},{"label":"ABCWY_Pooled","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.","primaryOutcome":{"measure":"Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY","timeFrame":"At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group)","effectByArm":[{"arm":"MenB_0_2_6 Group","deltaMin":13.3,"sd":null},{"arm":"MenB_0_6 Group","deltaMin":14.4,"sd":null},{"arm":"ACWY Group","deltaMin":79,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":17},"locations":{"siteCount":112,"countries":["United States","Australia","Canada","Czechia","Estonia","Finland","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["39647494"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":897},"commonTop":["Administration site pain","Fatigue","Headache","Nausea","Myalgia"]}}